Elan names ex-Glaxo boss as chairman
Mr Ingram — who also filled the role of vice chairman of pharmaceuticals at GlaxoSmithKline (formed by the merger of Wellcome and SmithKline Beecham ten years ago) — will formally assume the role at Elan’s next board meeting, on January 26.
He will succeed outgoing chairman, Kyran McLaughlin, who announced his decision to retire from Elan’s board back in April. Mr McLaughlin said he was “proud to be turning over the chairmanship to such a capable and high integrity leader”.
